公开(公告)号：EP4436593A1

公开(公告)日：2024-10-02

申请号：EP22817306.8

申请日：2022-11-21

Applicant: Ipsen Biopharm Limited

Inventor： MAIGNEL, Jaqueline Caroline ,  LEZMI, Stephane ,  MARTIN, Vincent

IPC: A61K38/48 ,  A61P1/00 ,  A61P1/16 ,  A61P1/18 ,  A61P13/02 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P25/02 ,  A61P25/04 ,  A61P29/00

CPC classification number: A61K38/4893 ,  A61P29/00 ,  A61P1/16 ,  A61P1/18 ,  A61P1/00 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P13/02 ,  A61P25/02 ,  A61P25/04

公开(公告)号：EP3782628B1

公开(公告)日：2024-08-07

申请号：EP20186939.3

申请日：2014-03-14

IPC: A61K31/7088 ,  A61K48/00 ,  C12N15/11 ,  C12N15/09

CPC classification number: C12N2760/1884120130101 ,  A61K48/005 ,  A61K31/7088 ,  A61K38/1709 ,  C07K14/47 ,  C12N15/113 ,  C12N2310/1420130101 ,  C12N2310/53120130101 ,  A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P11/00 ,  A61P13/00 ,  A61P13/02 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P17/14 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00 ,  A61P21/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P25/32 ,  A61P27/02 ,  A61P27/16 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  A61P5/00 ,  A61P5/38 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P3/10

公开(公告)号：EP3459958B1

公开(公告)日：2024-08-07

申请号：EP18186616.1

申请日：2014-12-12

IPC: C07F9/576 ,  C07F9/58

CPC classification number: C07F9/576 ,  C07F9/58 ,  A61P1/00 ,  A61P1/02 ,  A61P1/06 ,  A61P11/14 ,  A61P13/00 ,  A61P13/02 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P25/02 ,  A61P25/04 ,  A61P29/00 ,  A61P43/00 ,  A61P9/06

公开(公告)号：EP4400165A2

公开(公告)日：2024-07-17

申请号：EP24171612.5

申请日：2016-01-28

Applicant: Li Galli B.V.

Inventor： DE LAAT, Wilhelmus Nicolaas Gerardus Maria ,  VAN DER VAART, Carl Huibert

IPC: A61P13/10

CPC classification number: A61K38/28 ,  A61K9/0036 ,  A61K31/216 ,  A61K31/343 ,  A61K31/4168 ,  A61K31/428 ,  A61K31/465 ,  A61K31/485 ,  A61K31/57 ,  A61K45/06 ,  A61K31/4515 ,  A61K31/4725 ,  A61K31/565 ,  A61M31/002 ,  A61F6/06 ,  A61K38/24 ,  A61P13/02 ,  A61P15/12 ,  A61P15/18 ,  A61P25/04 ,  A61P25/16 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  A61P25/36 ,  A61P5/00 ,  A61P5/24 ,  A61P9/12 ,  A61P3/10

Abstract: The present invention relates to a vaginal drug delivery device configured for placement within the vagina, comprising a housing, at least one reservoir comprising a biologically active compound that is not normally administered via the vagina and means for the controlled release of the compound from the reservoir into the vagina. Suitably the vaginal device further comprising means for gathering physiological data of a person carrying the device in her vagina. Alternatively, the vaginal drug delivery device configured for placement within the vagina, comprises a housing and means for gathering physiological data of a person carrying the device in her vagina.

公开(公告)号：EP4372091A2

公开(公告)日：2024-05-22

申请号：EP24153079.9

申请日：2015-12-11

Applicant: Woolf, Tod M. ,  Lebedev, Alexandre ,  Hogrefe, Richard I.

Inventor： Woolf, Tod M. ,  Lebedev, Alexandre ,  Hogrefe, Richard I.

IPC: C12N15/85

CPC classification number: A61K48/00 ,  C12N15/111 ,  C12N2310/1120130101 ,  C12N2310/31520130101 ,  C12N2310/33320130101 ,  C12N2310/33520130101 ,  C12N2310/34420130101 ,  C12N2310/35120130101 ,  C12N2320/3420130101 ,  C12N15/102 ,  A61P1/00 ,  A61P11/00 ,  A61P13/02 ,  A61P13/12 ,  A61P21/04 ,  A61P25/00 ,  A61P25/14 ,  A61P25/28 ,  A61P27/02 ,  A61P3/00 ,  A61P35/00 ,  A61P3/06 ,  A61P3/08 ,  A61P43/00 ,  A61P7/00 ,  A61P9/00

Abstract: The present invention includes compositions and methods for the treatment of a medical condition or disease utilizing editing oligonucleotides. The editing oligonucleotides contain a an oligonucleotide strand of about 10 to about 50 nucleotides on each side of the editing moiety which may contain a sugar or linker that positions the active editing moiety in the proper location for hybridization to the target nucleic acid. The editing oligonucleotides may also contain at least one nucleotide sequence change from the targeted sequence in the genome. The method includes modifying a genomic sequence within a cell utilizing an editing oligonucleotide without additional proteins or nucleic acids to assist in the editing process. The editing oligonucleotide may comprise backbone modifications that increase the nuclease stability of the oligonucleotide as compared to unmodified oligonucleotides or oligonucleotides having three phosphorothioates on each terminus.

公开(公告)号：EP4368187A1

公开(公告)日：2024-05-15

申请号：EP22837760.2

申请日：2022-07-08

Applicant: Nippon Shinyaku Co., Ltd.

Inventor： ENYA, Yukiko ,  NUMAKURA, Yuki ,  OKAMOTO, Kentaro ,  AGATA, Kazuki

IPC: A61K31/70 ,  A61K31/7016 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/7125 ,  A61K47/26 ,  A61P13/02 ,  A61P13/12 ,  C12N15/113

CPC classification number: A61K31/70 ,  A61K31/7016 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/7125 ,  A61K47/26 ,  A61P13/02 ,  A61P13/12 ,  C12N15/113

Abstract: In one embodiment, the object of the present invention is to provide a precipitation suppressing agent for an antisense oligomer in urine of a subject to whom a pharmaceutical composition comprising an antisense oligomer has been administered, and a method for suppressing precipitation of an antisense oligomer in urine, in a subject to whom the pharmaceutical composition has been administered. In one embodiment, the present invention relates to a precipitation suppressing agent for an antisense oligomer in urine of a subject to whom a pharmaceutical composition comprising an antisense oligomer has been administered, wherein the precipitation suppressing agent comprises a sugar other than glucose and is used in an amount such that the concentration of the sugar in the pharmaceutical composition is 0.5 mg/mL to 3000 mg/mL.

公开(公告)号：EP2800578B1

公开(公告)日：2018-12-05

申请号：EP13733786.1

申请日：2013-01-04

Applicant: Boston Medical Center Corporation

Inventor： LU, Weining ,  FAN, Xueping ,  SALANT, David, J.

IPC: A61K38/17 ,  A61P13/12

CPC classification number: C12Q1/6883 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61P13/02 ,  A61P13/12 ,  C07K14/47 ,  C07K14/70503 ,  C07K16/18 ,  C07K2317/24 ,  C07K2319/70 ,  C12N15/113 ,  C12N15/115 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/16 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/70503 ,  G01N2800/347 ,  G06F19/00 ,  G06F19/20 ,  G06F19/3456 ,  G16H50/30 ,  Y02A90/24 ,  Y02A90/26 ,  A61K2300/00

Abstract: Provided herein are methods for the treatment of chronic kidney disease and proteinuria and for the diagnosis of chronic kidney disease and monitoring the effects of treatment on the progression of chronic kidney disease and proteinuria based on unexpected roles for the SLIT-ROBO signaling pathway in the regulation of podocyte F-actin cytoskeleton and foot process structure in the kidney.

公开(公告)号：EP3242680A2

公开(公告)日：2017-11-15

申请号：EP16703357.0

申请日：2016-01-07

Applicant: Linnane Pharma AB

Inventor： SVANBORG, Catharina ,  AMBITES, Ines

IPC: A61K38/17 ,  A61K31/00 ,  G01N33/48 ,  A61P13/02

CPC classification number: A61K38/2006 ,  A61K31/381 ,  A61K38/17 ,  A61P13/02 ,  C12Q1/68 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y304/24023 ,  G01N33/573 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/545 ,  G01N2333/96494 ,  G01N2800/348 ,  G01N2800/50

Abstract: A method for treating cystitis, in particular acute cystitis, comprising administering to a patient in need thereof, an effective amount of a reagent selected from the group consisting of IL-1β inhibitors and MMP inhibitors, or proteins selected from ASC or NLRP-3. Diagnostic methods are also described and claimed.

公开(公告)号：EP4400165A3

公开(公告)日：2024-09-25

申请号：EP24171612.5

申请日：2016-01-28

Applicant: Li Galli B.V.

Inventor： DE LAAT, Wilhelmus Nicolaas Gerardus Maria ,  VAN DER VAART, Carl Huibert

IPC: A61K31/216 ,  A61K38/28 ,  A61K31/343 ,  A61K31/4168 ,  A61K31/428 ,  A61K31/465 ,  A61K31/485 ,  A61K31/57

CPC classification number: A61K38/28 ,  A61K9/0036 ,  A61K31/216 ,  A61K31/343 ,  A61K31/4168 ,  A61K31/428 ,  A61K31/465 ,  A61K31/485 ,  A61K31/57 ,  A61K45/06 ,  A61K31/4515 ,  A61K31/4725 ,  A61K31/565 ,  A61M31/002 ,  A61F6/06 ,  A61K38/24 ,  A61P13/02 ,  A61P15/12 ,  A61P15/18 ,  A61P25/04 ,  A61P25/16 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  A61P25/36 ,  A61P5/00 ,  A61P5/24 ,  A61P9/12 ,  A61P3/10

Abstract: The present invention relates to a vaginal drug delivery device configured for placement within the vagina, comprising a housing, at least one reservoir comprising a biologically active compound that is not normally administered via the vagina and means for the controlled release of the compound from the reservoir into the vagina. Suitably the vaginal device further comprising means for gathering physiological data of a person carrying the device in her vagina. Alternatively, the vaginal drug delivery device configured for placement within the vagina, comprises a housing and means for gathering physiological data of a person carrying the device in her vagina.

公开(公告)号：EP3998067B1

公开(公告)日：2024-09-11

申请号：EP21204193.3

申请日：2016-11-09

IPC: A61K31/195 ,  A61K31/198 ,  A61K38/00 ,  A61K38/51 ,  A61P19/10 ,  A61K31/20 ,  A61K47/60 ,  A61P13/02 ,  A61P17/14 ,  A61P27/02

CPC classification number: A61K38/51 ,  A61K31/205 ,  C12Y402/01022 ,  A61K47/60 ,  A61P13/02 ,  A61P17/14 ,  A61P19/10 ,  A61P27/02 ,  A61P43/00